Compare CLNE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | ALT |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.3M | 421.5M |
| IPO Year | 2006 | 2005 |
| Metric | CLNE | ALT |
|---|---|---|
| Price | $2.04 | $2.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.32 | ★ $17.67 |
| AVG Volume (30 Days) | 1.3M | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $41,000.00 |
| Revenue This Year | $1.13 | N/A |
| Revenue Next Year | $22.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $1.73 | $2.56 |
| 52 Week High | $3.11 | $7.73 |
| Indicator | CLNE | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 44.10 |
| Support Level | N/A | $2.87 |
| Resistance Level | $2.40 | $4.19 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 41.24 | 41.46 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.